Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Crit Care ; 28(1): 40, 2024 02 05.
Artículo en Inglés | MEDLINE | ID: mdl-38317262

RESUMEN

BACKGROUND: Ventilator associated pneumonia (VAP) due to wild-type AmpC-producing Enterobacterales (wtAE) is frequent in intensive care unit (ICU) patients. Despite a low level of evidence, definitive antimicrobial therapy (AMT) with third generation cephalosporins (3GCs) or piperacillin is discouraged. METHODS: Observational prospective study including consecutive wtAE VAP patients in 20 French ICUs. The primary objective was to assess the association of the choice of definitive AMT, i.e. piperacillin ± tazobactam (PTZ), 3GCs or other molecule (4GCs, carbapenems, quinolones, cotrimoxazole; control group), with treatment success at day-7. Recurrence of infection was collected as a secondary outcome, and analyzed accounting for the competing risk of death. RESULTS: From February 2021 to June 2022, 274 patients were included. Enterobacter cloacae was the most prevalent specie (31%). Seventy-eight patients (28%) had PTZ as definitive AMT while 44 (16%) had 3GCs and 152 (56%) were classified in the control group. Day-7 success rate was similar between the 3 groups (74% vs. 73% vs. 68% respectively, p = 0.814). Recurrence probability at day-28 was 31% (95% CI 21-42), 40% (95% CI 26-55) and 21% (95% CI 15-28) for PTZ, 3GCs and control groups (p = 0.020). In multivariable analysis, choice of definitive AMT was not associated with clinical success, but definitive AMT with 3GCs was associated with recurrence at day-28 [csHR(95%CI) 10.9 (1.92-61.91)]. CONCLUSION: Choice of definitive antimicrobial therapy was not associated with treatment success at day 7. However, recurrence of pneumonia at day-28 was higher in patients treated with third generation cephalosporins with no differences in mortality or mechanical ventilation duration.


Asunto(s)
Antibacterianos , Neumonía Asociada al Ventilador , Humanos , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Estudios Prospectivos , Neumonía Asociada al Ventilador/tratamiento farmacológico , Enfermedad Crítica/terapia , Piperacilina/uso terapéutico , Combinación Piperacilina y Tazobactam/uso terapéutico , Unidades de Cuidados Intensivos
2.
Lancet Respir Med ; 11(4): 319-328, 2023 04.
Artículo en Inglés | MEDLINE | ID: mdl-36693402

RESUMEN

BACKGROUND: Fasting is frequently imposed before extubation in patients in intensive care units, with the aim to reduce risk of aspiration. This unevaluated practice might delay extubation, increase workload, and reduce caloric intake. We aimed to compare continued enteral nutrition until extubation with fasting before extubation in patients in the intensive care unit. METHODS: We conducted an open-label, cluster-randomised, parallel-group, non-inferiority trial in 22 intensive care units in France. Patients aged 18 years or older were eligible for enrolment if they had received invasive mechanical ventilation for at least 48 h in the intensive care unit and received prepyloric enteral nutrition for at least 24 h at the time of extubation decision. Centres were randomly assigned (1:1) to continued enteral nutrition until extubation or 6-h fasting with concomitant gastric suctioning before extubation, to be applied for all patients within the unit. Masking was not possible because of the nature of the trial. The primary outcome was extubation failure (composite criteria of reintubation or death) within 7 days after extubation, assessed in both the intention-to-treat and per-protocol populations. The non-inferiority margin was set at 10%. Pneumonia within 14 days of extubation was a key secondary endpoint. This trial is now complete and is registered with ClinicalTrials.gov, NCT03335345. FINDINGS: Between April 1, 2018, and Oct 31, 2019, 7056 patients receiving enteral nutrition and mechanical ventilation were admitted to the intensive care units and 4198 were assessed for eligibility. 1130 patients were enrolled and included in the intention-to-treat population and 1008 were included in the per-protocol population. In the intention-to-treat population, extubation failure occurred in 106 (17·2%) of 617 patients assigned to receive continued enteral nutrition until extubation versus 90 (17·5%) of 513 assigned to fasting, meeting the a priori defined non-inferiority criterion (absolute difference -0·4%, 95% CI -5·2 to 4·5). In the per-protocol population, extubation failure occurred in 101 (17·0%) of 595 patients assigned to receive continued enteral nutrition versus 74 (17·9%) of 413 assigned to fasting (absolute difference -0·9%, 95% CI -5·6 to 3·7). Pneumonia within 14 days of extubation occurred in ten (1·6%) patients assigned to receive continued enteral nutrition and 13 (2·5%) assigned to fasting (rate ratio 0·77, 95% CI 0·22 to 2·69). INTERPRETATION: Continued enteral nutrition until extubation in critically ill patients in the intensive care unit was non-inferior to a 6-h fasting maximum gastric vacuity strategy comprising continuous gastric tube suctioning, in terms of extubation failure within 7 days (a patient-centred outcome), and thus represents a potential alternative in this population. FUNDING: French Ministry of Health. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.


Asunto(s)
Extubación Traqueal , Nutrición Enteral , Humanos , Respiración Artificial , Unidades de Cuidados Intensivos , Ayuno , Resultado del Tratamiento
3.
BMJ Case Rep ; 12(6)2019 Jun 06.
Artículo en Inglés | MEDLINE | ID: mdl-31175111

RESUMEN

We report a case of cefepime neurotoxicity characterised by myoclonic status epilepticus with coma, in a context of acute renal failure and requiring one discontinuous conventional haemodialysis. Cefepime is a fourth-generation broad-spectrum cephalosporin mainly used to treat hospital-acquired Gram-negative infections. Acute neurotoxicity is an increasingly reported adverse effect which occurs predominantly in patients with renal impairment. Renal replacement therapy has been proposed to treat this condition.


Asunto(s)
Lesión Renal Aguda/terapia , Antibacterianos/efectos adversos , Cefepima/efectos adversos , Epilepsias Mioclónicas/inducido químicamente , Estado Epiléptico/inducido químicamente , Lesión Renal Aguda/inducido químicamente , Anciano de 80 o más Años , Antibacterianos/toxicidad , Bronquiectasia/tratamiento farmacológico , Cefepima/toxicidad , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Epilepsias Mioclónicas/fisiopatología , Resultado Fatal , Femenino , Humanos , Síndromes de Neurotoxicidad/complicaciones , Síndromes de Neurotoxicidad/diagnóstico , Diálisis Renal , Estado Epiléptico/fisiopatología
4.
BMJ Case Rep ; 20182018 Oct 16.
Artículo en Inglés | MEDLINE | ID: mdl-30333198

RESUMEN

Meningococcal pericarditis is a rare but severe form of acute purulent pericarditis. It is a classic complication of Neisseria meningitidis of serotype W135, usually occurring in pilgrims to Mecca and their household contacts. This severe form of meningococcaemia is difficult to diagnose and evolves frequently and gradually towards a tamponade, requiring emergency drainage. We report a case of meningococcal pericarditis caused by N. meningitidis W135 in an immunocompetent patient, without any other organ involvement especially meningeal, requiring pericardium drainage in emergency and then intrapericardial fibrinolysis.


Asunto(s)
Fibrinólisis/fisiología , Neisseria meningitidis/aislamiento & purificación , Pericarditis Constrictiva/diagnóstico por imagen , Pericardio/microbiología , Drenaje/métodos , Ecocardiografía Transesofágica/métodos , Humanos , Masculino , Infecciones Meningocócicas/microbiología , Persona de Mediana Edad , Pericarditis Constrictiva/tratamiento farmacológico , Pericarditis Constrictiva/microbiología , Pericarditis Constrictiva/cirugía , Pericardio/efectos de los fármacos , Pericardio/cirugía , Resultado del Tratamiento , Activador de Plasminógeno de Tipo Uroquinasa/administración & dosificación , Activador de Plasminógeno de Tipo Uroquinasa/uso terapéutico
5.
Presse Med ; 43(7-8): e221-31, 2014.
Artículo en Francés | MEDLINE | ID: mdl-24785139

RESUMEN

BACKGROUND: In 2011, 1.7 % of the French population was receiving a Vitamine K Antagonist (VKA) anticoagulant therapy. VKA related adverse events are the first cause for iatrogenic events in France. Anticoagulant bridging period is a period at both increased risk for thromboembolic and bleeding events. The Haute Autorité de santé (HAS) established in 2008 recommendations in order to help physicians to manage anticoagulant therapy in case of invasive procedure or surgery, according to the procedure and the indication of VKA. PRIMARY AIM: To assess anticoagulant treatment management by general physicians when an invasive procedure or a planned surgery in a patient receiving long-term VKA Data have been compared to HAS recommendations. METHODS: A descriptive transversal survey performed in general physicians à at the conference held in Nice in 2012. An anonymous questionnaire was built, including questions about clinical situations and knowledge questions. RESULTS: Eighty-eight out of 200 submitted questionnaires have been completed (44%). Overall, 4.5% of questioned physicians have managed fully in accordance with HAS recommendations the 6 clinical situations cliniques about patients receiving long-term VKA for atrial fibrillation, recurrent pulmonary embolism, and mechanical valvular prothesis. Bridgings using Low Molecular Weight Heparins have been excessively proposed by asked physicians and bridging prescription was most of the time wrong (9% correct). Otherwise, no physician has answered correctly all theoretical questions; patients at high and low thromboembolic risk are not well distinguished; 64% of physicians think they are influenced by specialists who have prescribed the procedure. DISCUSSION: Few physicians manage VKA therapy in accordance with HAS recommendations in case of invasive procedure. There are many hypotheses: bad knowledge of recommendations, overestimation of the thromboembolic risk related to VKA stopping during the period of the invasive procedure, underestimation of the risk of bleeding related to the bridging period of time; influence of specialists. We propose a decisional algorithm in order to improve the implementation of HAS recommendations in usual care.


Asunto(s)
Anticoagulantes/uso terapéutico , Medicina General , Pautas de la Práctica en Medicina , Procedimientos Quirúrgicos Operativos , Tromboembolia/tratamiento farmacológico , Vitamina K/antagonistas & inhibidores , Algoritmos , Implantación de Prótesis de Válvulas Cardíacas , Humanos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...